Studies heart failure types over time using samples, scans and health data
Follows adults with several types of heart failure to learn how each develops.
Plain-language title generated from the registry record
Registry title: Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Massachusetts General HospitalBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT03480633
- Record updated
- 31 August 2026
- Original description
In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.Read full original descriptionShow less
Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) Study
In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.
Inclusion: 18 years and older; History of clinical symptoms consistent with HF and at least one of the following supporting evidence of HF:; NT-proBNP > 125 pg/mL; BNP > 35 pg/mL; Capillary wedge pressure ≥ 15 mmHg on right heart catheterization or CI <2.8 L/min/m2; LVEDP ≥ 15 mmHg; Radiographic evidence of pulmonary edema; Improvement in symptoms with diuretic initiation of increase; CPET evidence of cardiac etiology of symptoms; HFpEF: LVEF ≥ 50% HFrEF: LVEF <50%.
Exclusion: End stage renal disease on dialysis.